As of today (2024-04-19), Amgen's share price is $265.37. Amgen's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-84.12. Hence, Amgen's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Amgen's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Amgen's highest Price to Tangible Book Ratio was 73.95. The lowest was 22.27. And the median was 67.12.
AMGN's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.285 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Amgen's share price is $265.37. Amgen's Book Value per Sharefor the quarter that ended in Dec. 2023 was $11.64. Hence, Amgen's P/B Ratio of today is 22.80.
Amgen Price-to-Tangible-Book Historical Data
The historical data trend for Amgen's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
-
-
-
-
Amgen Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
-
-
-
-
-
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Price-to-Tangible-Book Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Amgen's Price-to-Tangible-Book falls into.
Amgen Price-to-Tangible-Book Calculation
Amgen's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Amgen Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Amgen's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 